New hope for Hard-to-Treat prostate cancer: drug combo trial launches

NCT ID NCT07592910

Not yet recruiting Disease control Sponsor: Prostate Cancer Clinical Trials Consortium Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests whether adding mevrometostat to enzalutamide can slow cancer growth in 60 men with metastatic castration-resistant prostate cancer who have already been treated with similar drugs. Participants will take both drugs orally. The main goal is to see how long the cancer stays under control.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Mevrometostat (PF-06821497) and enzalutamide (Xtandi)
What this could lead to: If successful, this combination could delay cancer progression in men with advanced prostate cancer who have already tried similar treatments.
What could go wrong: This is a small, early-phase trial with no control group, so results may not be conclusive. The combination may cause side effects or fail to improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATE RESISTANT PROSTATE CANCER (MCRPC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

adenocarcinoma castration-resistant prostate carcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC CASTRATE RESISTANT PROSTATE CANCER (MCRPC) PROSTATE CANCER (ADENOCARCINOMA)

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.